$1.72 EPS Expected for Celgene Corporation (CELG)

October 12, 2017 - By Dolores Ford

 $1.72 EPS Expected for Celgene Corporation (CELG)
Investors sentiment increased to 1.34 in Q2 2017. Its up 0.21, from 1.13 in 2017Q1. It increased, as 60 investors sold Celgene Corporation shares while 390 reduced holdings. 110 funds opened positions while 494 raised stakes. 602.51 million shares or 1.81% more from 591.78 million shares in 2017Q1 were reported.
Taurus Asset Mngmt Limited Liability owns 2.46% invested in Celgene Corporation (NASDAQ:CELG) for 120,795 shares. 840 were accumulated by First Financial Corporation In. Burt Wealth owns 945 shares for 0.08% of their portfolio. Veritable Limited Partnership reported 0.15% in Celgene Corporation (NASDAQ:CELG). Btim has 8,592 shares. Huntington Fincl Bank reported 0.3% of its portfolio in Celgene Corporation (NASDAQ:CELG). Arvest Bancshares Division invested in 1.12% or 113,865 shares. 5,421 were accumulated by Granite Investment Prtnrs. The Florida-based Texas Yale Cap Corp has invested 0.03% in Celgene Corporation (NASDAQ:CELG). Carmignac Gestion has invested 8% in Celgene Corporation (NASDAQ:CELG). Tiverton Asset Ltd Com reported 247,766 shares or 1.74% of all its holdings. Guardian Life Of America reported 1,766 shares stake. Altfest L J And Inc invested in 0.32% or 4,113 shares. Iberiabank accumulated 0.42% or 10,901 shares. Oaktop Mgmt Ii Limited Partnership owns 2.09M shares or 49.74% of their US portfolio.

Since June 15, 2017, it had 0 insider purchases, and 3 selling transactions for $2.36 million activity. 4,785 shares valued at $575,038 were sold by VESSEY RUPERT on Thursday, June 15. Friedman Michael A also sold $625,000 worth of Celgene Corporation (NASDAQ:CELG) on Saturday, June 17.

Analysts expect Celgene Corporation (NASDAQ:CELG) to report $1.72 EPS on October, 26.They anticipate $0.33 EPS change or 23.74 % from last quarter’s $1.39 EPS. CELG’s profit would be $1.35B giving it 20.15 P/E if the $1.72 EPS is correct. After having $1.68 EPS previously, Celgene Corporation’s analysts see 2.38 % EPS growth. About 1.65M shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since October 12, 2016 and is uptrending. It has outperformed by 0.30% the S&P500.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 27 analysts covering Celgene Corporation (NASDAQ:CELG), 23 have Buy rating, 1 Sell and 3 Hold. Therefore 85% are positive. Celgene Corporation had 78 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer on Thursday, July 27 with “Buy”. The firm has “Strong-Buy” rating given on Tuesday, September 1 by Raymond James. Stifel Nicolaus maintained it with “Buy” rating and $13900 target in Thursday, July 6 report. RBC Capital Markets maintained Celgene Corporation (NASDAQ:CELG) on Wednesday, October 4 with “Buy” rating. On Tuesday, September 12 the stock rating was maintained by Cowen & Co with “Buy”. The firm earned “Buy” rating on Thursday, July 27 by Canaccord Genuity. As per Tuesday, September 26, the company rating was maintained by Cantor Fitzgerald. On Wednesday, July 26 the stock rating was maintained by Mizuho with “Buy”. The firm has “Buy” rating by SunTrust given on Thursday, January 7. The stock has “Buy” rating by Citigroup on Thursday, February 25.

Celgene Corporation is an integrated global biopharmaceutical company. The company has market cap of $108.47 billion. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. It has a 43.11 P/E ratio. The Company’s commercial-stage products include REVLIMID , POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide).

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nj.com which released: “SAGE Eldercare receives donation from Celgene Corporation” on October 12, 2017, also Businesswire.com with their article: “Celgene Corporation to Announce Third Quarter 2017 Results on October 26, 2017 …” published on October 02, 2017, Seekingalpha.com published: “Celgene Presents Strong Potential Despite Clinical Hold Setback” on September 28, 2017. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Seekingalpha.com and their article: “Celgene Could Be A $200 Stock” published on October 02, 2017 as well as Fool.com‘s news article titled: “Better Buy: Celgene Corporation vs. Merck & Co., Inc.” with publication date: September 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com